| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
2,2,14,14-Tetramethyl-8-oxopentadecanedioic acid can be used for the research of cardiovascular diseases, dyslipidemias, dysproteinemias, and glucose metabolism disorders. Its targets may include enzymes involved in lipid and glucose metabolism. It is a ketone compound.
|
|---|---|
| ln Vitro |
In vitro, 2,2,14,14-Tetramethyl-8-oxopentadecanedioic acid is a research compound with potential applications in metabolic disease research. Detailed in vitro activity data are limited. It may modulate enzymes involved in lipid and glucose metabolism.
|
| ln Vivo |
In vivo, 2,2,14,14-Tetramethyl-8-oxopentadecanedioic acid has potential applications in cardiovascular disease, dyslipidemia, and diabetes research. Animal studies are needed to confirm its in vivo efficacy and safety.
|
| Enzyme Assay |
Cell-free assays for 2,2,14,14-Tetramethyl-8-oxopentadecanedioic acid: enzyme inhibition assays for targets involved in lipid and glucose metabolism (e.g., lipases, glucosidases) can be performed. The compound is incubated with enzyme and substrate, and activity is measured spectrophotometrically. IC50 values are calculated from dose-response curves.
|
| Cell Assay |
Cellular assays for 2,2,14,14-Tetramethyl-8-oxopentadecanedioic acid: cells (e.g., hepatocytes, adipocytes) are cultured and treated with the compound at concentrations of 0.1-100 µM for 24-72 hours. Lipid accumulation is measured by Oil Red O staining. Glucose uptake is measured using fluorescent glucose analogs. Cell viability is assessed by MTT assay.
|
| Animal Protocol |
In vivo animal studies for 2,2,14,14-Tetramethyl-8-oxopentadecanedioic acid: animal models of cardiovascular disease, dyslipidemia, or diabetes (e.g., high-fat diet-fed mice) would be used. Animals are administered the compound orally at doses of 10-50 mg/kg. Serum lipid profiles, blood glucose levels, and other metabolic parameters are assessed.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of 2,2,14,14-Tetramethyl-8-oxopentadecanedioic acid: as a small molecule (molecular weight 342.47), it may have moderate oral bioavailability. It is likely metabolized in the liver and excreted via the kidneys. Tissue distribution and elimination pathways require further investigation.
|
| Toxicity/Toxicokinetics |
Toxicity of 2,2,14,14-Tetramethyl-8-oxopentadecanedioic acid: comprehensive toxicity data are limited. It is for research use only and not approved for clinical use. Standard laboratory safety precautions should be followed.
|
| References |
[1]. Jean-Louis H. Dasseux, et al. Ketone compounds and compositions for cholesterol management and related uses. WO2002030860A2.
|
| Additional Infomation |
2,2,14,14-Tetramethyl-8-oxopentadecanedioic acid is a research compound with potential applications in metabolic disease research. It is a ketone compound. No clinical trials or FDA approvals have been reported.
|
| Molecular Formula |
C19H34O5
|
|---|---|
| Molecular Weight |
342.47
|
| Exact Mass |
342.24
|
| CAS # |
413624-71-2
|
| PubChem CID |
11336822
|
| Appearance |
Typically exists as solid at room temperature
|
| Melting Point |
82 - 83 °C
|
| LogP |
4.3
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
14
|
| Heavy Atom Count |
24
|
| Complexity |
386
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CC(C)(CCCCCC(=O)CCCCCC(C)(C)C(O)=O)C(O)=O
|
| InChi Key |
NHVXRVOYVVPVDU-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C19H34O5/c1-18(2,16(21)22)13-9-5-7-11-15(20)12-8-6-10-14-19(3,4)17(23)24/h5-14H2,1-4H3,(H,21,22)(H,23,24)
|
| Chemical Name |
2,2,14,14-tetramethyl-8-oxopentadecanedioic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 100 mg/mL (292.00 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (7.30 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (7.30 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (7.30 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.9200 mL | 14.5998 mL | 29.1996 mL | |
| 5 mM | 0.5840 mL | 2.9200 mL | 5.8399 mL | |
| 10 mM | 0.2920 mL | 1.4600 mL | 2.9200 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
